Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer
- 1 November 1996
- Vol. 14 (16), 1485-1494
- https://doi.org/10.1016/s0264-410x(96)00117-x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferationThe Lancet, 1995
- Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.Proceedings of the National Academy of Sciences, 1994
- Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 proteinInternational Immunology, 1994
- Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7Virology, 1991
- A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cellsNucleic Acids Research, 1990
- Characterization of an efficient coronavirus ribosomal frameshifting signal: Requirement for an RNA pseudoknotCell, 1989
- Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.Proceedings of the National Academy of Sciences, 1988
- Isolation of a transforming sequence from a human bladder carcinoma cell lineCell, 1982
- Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus geneCell, 1981
- Complications of Smallpox Vaccination, 1968New England Journal of Medicine, 1969